Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q2 2019 · 10-Q
Revenue$243.20M$243.20M+10.4% vs Q2 2018 Net Income-$9.50M-$9.50MN/M vs Q2 2018 EPS Diluted-$0.18-$0.18N/M vs Q2 2018 Gross Profit-$7,000,000N/M Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flowderived-$35,800,000N/M Free Cash Flowderived-$49,900,000N/M Margins · derivedGross margin-2.9%−33.2 pt vs Q2 2018
Operating margin-2.9%−33.2 pt vs Q2 2018
Net margin-3.9%−26.7 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 2, 2019 · 33 d after period end